A recent study from the Cardiovascular Division of the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; and Massachusetts General Hospital Cardiovascular Division and Harvard Medical School, MA, USA shows that “miR-222 Is Necessary for Exercise-Induced Cardiac Growth and Protects against Pathological Cardiac Remodeling.” This study was published in the 7 April 2015 issue of Cell Metabolism (the number 1 journal in the field of Metabolism) by Prof Rosenzweig A, Xiaojun Liu and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Rescuing the malfunctioning cardiomyocytes in myocardial patients: Celecoxib, a COX-2 inhibitor, mimicks the effects of exercise, regenerates cardiomyocytes and improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)
Significance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and were expected to be doubled by 2015; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find a safe treatment methodology to induce regeneration of cardiomyocytes that were lost in Myocardial patients.
This study suggests, for the first time, that Celecoxib, by increasing the expression of its target gene miRNA-222, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardimyocyte survival/regeneration. Besides, it may increase cardiac repair and growth; and decrease remodeling after ischemic injury. Thereby, Celecoxib may prevent ageing-associated decline in cardiac function. Thus, pharmacological formulations encompassing “Celecoxib or its analogues” (with less side effects) may be used to improve cardiac function after myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Rescuing the malfunctioning cardiomyocytes in myocardial patients: Celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug, mimicks the effects of exercise, regenerates cardiomyocytes and improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 6/May/2015, 21.18, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Celecoxib increases the expression of PNUTS/PPP1R10
